ChemDiv shares an update on its Cutting-edge Biology Facility in Portugal

ChemDiv Inc. has shared an exciting update on its cutting-edge biology facility located at Biocant Park in Cantanhede, Portugal. Since its establishment in 2022, the facility has made significant progress and has expanded its capabilities to contribute actively to ChemDiv’s drug discovery and development solutions.

The state-of-the-art facility boasts a world-class infrastructure covering an area of over 3,000 square meters. Equipped with advanced technologies, the facility offers a range of services including assay development, high-throughput screening, hit identification and profiling, pharmacology, and discovery biology. With the incorporation of automation, bioinformatics, and screening technologies, the facility ensures the delivery of high-quality data and rapid results to clients.

The success of the facility can be attributed to the expertise of its highly skilled team of scientists. These scientists specialize in various aspects of drug discovery such as assay development, high-throughput screening, pharmacology, and medicinal chemistry. Their extensive industry knowledge and successful track records enable ChemDiv to collaborate closely with clients and cater to their specific requirements.

ChemDiv’s cutting-edge biology facility in Portugal aims to foster innovation and collaboration. The facility is designed to be flexible and customizable, allowing it to meet a diverse range of client needs. Additionally, clients have access to ChemDiv’s extensive compound collection, which comprises over 1 million compounds, providing further support for their drug discovery projects.

Quality and data integrity are paramount at ChemDiv’s biology facility, with robust quality control measures and monitoring procedures in place. The highly trained technicians adhere to the highest standards of best practice to ensure the reliability and accuracy of the data.

In conclusion, ChemDiv’s cutting-edge biology facility in Portugal has achieved significant progress and expansion since its inception in 2022. With its world-class infrastructure, expert scientists, and emphasis on quality, the facility is well-positioned to provide advanced drug discovery services to clients in the pharmaceutical and biotech industries.